Cargando…

Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment

Post-exposure risk assessment of chemical and environmental stressors is a public health challenge. Linking exposure to health outcomes is a 4-step process: exposure assessment, hazard identification, dose response assessment, and risk characterization. This process is increasingly adopting “in sili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mumtaz, Moiz, Fisher, Jeffrey, Blount, Benjamin, Ruiz, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317240/ https://www.ncbi.nlm.nih.gov/pubmed/22523493 http://dx.doi.org/10.1155/2012/904603

Ejemplares similares

Development of a Human Physiologically Based Pharmacokinetic (PBPK) Toolkit for Environmental Pollutants
por: Ruiz, Patricia, et al.
Publicado: (2011)

Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.
por: Krewski, D, et al.
Publicado: (1994)

Unraveling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
por: Yang, Xiaoxia, et al.
Publicado: (2015)

PBPK model reporting template for chemical risk assessment applications
por: Tan, Yu-Mei, et al.
Publicado: (2020)

Physiologically based pharmacokinetics and cancer risk assessment.
por: Andersen, M E, et al.
Publicado: (1994)

Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults
por: Yang, Xiaoxia, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids
por: Mallick, Pankajini, et al.
Publicado: (2020)

The Role of “Physiologically Based Pharmacokinetic Model (PBPK)” New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment
por: Deepika, Deepika, et al.
Publicado: (2023)

Using Physiologically-Based Pharmacokinetic Models to Incorporate Chemical and Non-Chemical Stressors into Cumulative Risk Assessment: A Case Study of Pesticide Exposures
por: Wason, Susan C., et al.
Publicado: (2012)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in Children
por: Jiang, X-L, et al.
Publicado: (2013)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites.
por: Fisher, J W
Publicado: (2000)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine
por: He, Lixia, et al.
Publicado: (2022)

Adapting physiologically-based pharmacokinetic models for machine learning applications
por: Habiballah, Sohaib, et al.
Publicado: (2023)

The Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment
por: Lu, Chensheng, et al.
Publicado: (2010)

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach
por: Ezuruike, Udoamaka, et al.
Publicado: (2018)

Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations
por: Yu, Yanke, et al.
Publicado: (2021)

Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy
por: George, Blessy, et al.
Publicado: (2020)

Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment.
por: Clewell, H J, et al.
Publicado: (2000)

Comparison of the Use of a Physiologically Based Pharmacokinetic Model and a Classical Pharmacokinetic Model for Dioxin Exposure Assessments
por: Emond, Claude, et al.
Publicado: (2005)

Pharmacokinetics, chemical interactions, and toxicological risk assessment in perspective.
por: Blancato, J N
Publicado: (1994)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol
por: Levitt, David G
Publicado: (2002)

Development and Application of a Physiologically Based Pharmacokinetic Model for Diclazuril in Broiler Chickens
por: Yang, Fang, et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

A Physiologically Based Pharmacokinetic Model for Predicting Diazepam Pharmacokinetics after Intravenous, Oral, Intranasal, and Rectal Applications
por: Khalid, Sundus, et al.
Publicado: (2021)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
por: Song, Yoo-Kyung, et al.
Publicado: (2021)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Human physiologically based pharmacokinetic model for propofol
por: Levitt, David G, et al.
Publicado: (2005)

Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Ghallab, Ahmed
Publicado: (2015)

Examination of Physiologically‐Based Pharmacokinetic Models of Rosuvastatin
por: Bowman, Christine M., et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling of Extracellular Vesicles
por: Kumar, Prashant, et al.
Publicado: (2023)

Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics
por: Zakaria, Zaril, et al.
Publicado: (2018)

Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT—Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment
por: Taylor, Michael D., et al.
Publicado: (2012)

Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and Simulation
por: Kuemmel, Colleen, et al.
Publicado: (2019)

Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition
por: Duan, Peng, et al.
Publicado: (2018)

The Application of a Physiologically Based Toxicokinetic Model in Health Risk Assessment
por: Chen, Mengting, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures.
por: Krishnan, Kannan, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_9a50arbb3vbg56di1impd30ka6